December, 2012
CURRICULUM VITÆ MARK DAVID WATANABE
OFFICE INFORMATION: Department of Pharmacy Practice Northeastern University – 140 The Fenway, R218 360 Huntington Avenue Boston, MA 02115 (617) 373-3203 (617) 373-7655 (FAX) e-mail: [email protected]
EDUCATION: 1990 Ph.D., Pharmaceutical Chemistry University of California, San Francisco Ph.D. dissertation: Watanabe MD. The role of carbon radicals in the metabolism of hydrazines by cytochrome P-450 systems. University of California, San Francisco, 1990 (Advisor: Paul R. Ortiz de Montellano, Ph.D.) 1982 Pharm.D., Pharmacy University of California, San Francisco 1978 B.S., Biological Sciences University of California, Irvine 1977 B.A., Chemistry University of California, Irvine
POSTGRADUATE TRAINING:
1987-1989: American Society of Hospital Pharmacists Accredited Specialty Residency and Clinical Sciences Fellowship, Psychiatric Pharmacy; The University of Texas at Austin & San Antonio State Hospital
PHARMACIST LICENSURE: California Oregon Illinois Massachusetts
BOARD CERTIFICATION: 1996-2018 Board of Pharmacy Specialties Certification in Psychiatric Pharmacy
TEACHING EXPERIENCE:
2010-present Assistant Clinical Professor, Pharmacy Practice (Full-time appointment) School of Pharmacy / Bouvé College of Health Sciences Northeastern University Boston, MA
2008-2010 Adjunct Clinical Assistant Professor, Pharmacy Practice Massachusetts College of Pharmacy & Health Sciences Worcester, MA
2008-2010 Adjunct Assistant Clinical Professor, Pharmacy Practice School of Pharmacy / Bouvé College of Health Sciences Northeastern University Boston, MA
2003-2008 Assistant Clinical Specialist / Assistant Clinical Professor, Pharmacy Practice School of Pharmacy / Bouvé College of Health Sciences Northeastern University Boston, MA
2004 Adjunct Clinical Faculty Albany College of Pharmacy, Union University Albany, NY
1998-2003 Assistant Clinical Professor WOS, Clinical Pharmacy School of Pharmacy University of California, San Francisco San Francisco, CA
2000-2002 Instructor, Clinical Pharmacology California School of Professional Psychology / Alliant University Alameda, CA
1989-1998 Clinical Assistant Professor, Pharmacy Practice (Full-time appointment) College of Pharmacy The University of Illinois at Chicago Chicago, IL
1987-1989 Clinical Instructor, Pharmacy College of Pharmacy The University of Texas at Austin Austin, TX / San Antonio, TX
Dr. Mark David Watanabe • Curriculum Vitæ • December, 2012 • page 2
1979-1986 Graduate Student Teaching Assistant, Pharmacy and Pharmaceutical Chemistry Tutor for Pharmacy Students in Organic, Physical, and Medicinal Chemistry Department of Pharmaceutical Chemistry University of California, San Francisco San Francisco, CA
CLINICAL PRACTICE AND EMPLOYMENT EXPERIENCE:
2010-present Psychiatric Pharmacotherapy Consultant, Massachusetts Department of Mental Health (Dr. Solomon Carter Fuller Mental Health Center) (Boston, MA)
2008-2010 Clinical Consultant Pharmacist, Clinical Pharmacy Services, Commonwealth Medicine, University of Massachusetts Medical School (Shrewsbury, MA / Boston, MA)
2007-2008 Clinical Pharmacist Specialist, Behavioral Health, Harbor Health Services Inc. (Boston, MA)
2006 Psychiatric Pharmacotherapy Consultant, Massachusetts Department of Mental Health (Erich Lindemann Mental Health Center and Dr. Solomon Carter Fuller Mental Health Center) (Boston, MA)
2003-2005 Psychiatric Pharmacotherapy Consultant, Goldfarb Behavioral Health Clinic, Lemuel Shattuck Hospital, Massachusetts Department of Public Health (Boston, MA)
1999-2003 Clinical/Administrative Pharmacist Specialist in Psychiatry, Alameda County Behavioral Health Care Services (Oakland, CA)
1998-1999 Medical Sciences Manager in Neuroscience for Northern California, Nevada, and Hawai‘i, Bristol-Myers Squibb Company, Princeton, NJ (field staff based in San Francisco, CA)
1994-1998 Clinical Pharmacy Consultant-in-Residence, Division of Mental Health and Developmental Disabilities, Illinois Department of Human Services (Chicago, IL / Springfield, IL)
1993-1994 Pharmacotherapist, Neuropsychiatry Service, Department of Psychiatry, University of Illinois Hospital and Clinics (Chicago, IL)
1989-1993 Clinical / Research Pharmacotherapist, Illinois State Psychiatric Institute (Chicago, IL)
1987-1989 Clinical Pharmacologist, San Antonio State Hospital (San Antonio, TX)
1982-1987 Staff Pharmacist, on-call part-time, Kaiser Permanente Medical Center (San Francisco, CA / South San Francisco, CA)
1978-1982 Doctor of Pharmacy Program internships, University of California, San Francisco School of Pharmacy (San Francisco, CA)
Dr. Mark David Watanabe • Curriculum Vitæ • December, 2012 • page 3
ADMINISTRATIVE / PUBLIC SERVICE EXPERIENCE:
2012-2014 Editorial Board member, Psychiatric Pharmacy Review Course, College of Psychiatric and Neurologic Pharmacists, Lincoln, NE
2010-2012 Faculty advisor, Student National Pharmaceutical Association, Bouvé College of Health Sciences School of Pharmacy, Northeastern University, Boston, MA
2008 Peer reviewer, National Institutes of Health Rapid Access to Investigational Development Pilot Program
2007-present Reviewer, Journal of the American Pharmacists Association, American Pharmacists Association; Washington, DC
2007-2008 Faculty advisor, Phi Lambda Sigma Leadership Society, Bouvé College of Health Sciences School of Pharmacy, Northeastern University, Boston, MA
2003-2008 Faculty committees, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA: •Pharmacy Admissions and Retention Committee (2004-2008) •Graduate Committee for Pharm.D. and Professional Programs (2005-2008) •Bouvé Advisory Council to the School of Professional and Continuing Studies (2006-2008)
2002-2004 Section co-editor, Psychiatric Disorders, In: Applied Therapeutics – The Clinical Use of Drugs, 8th edition (Kimble MA, Young LY, eds.), Lippincott Williams & Wilkins; Baltimore, MD
2000-present Reviewer, Psychiatric Services (formerly Hospital and Community Psychiatry), American Psychiatric Association; Washington, DC
1999 Reviewer, The Rx Consultant, Continuing Education Network, Inc.; Martinez, CA
1997-2001 Section co-editor, Psychiatric Disorders, In: Applied Therapeutics – The Clinical Use of Drugs, 7th edition (Kimble MA, Young LY, eds.), Applied Therapeutics, Inc.; Vancouver, WA
1997-1998 Reviewer, UHC Drug Monograph Series, University HealthSystem Consortium; Oak Brook, IL
1997-1998 Risperdal® Advisory Board member, Janssen Pharmaceutica; Titusville, NJ
Dr. Mark David Watanabe • Curriculum Vitæ • December, 2012 • page 4
1996 Participant, Item Development Workshop, Board Certification Examination in Psychiatric Pharmacy Practice, Dallas / Fort Worth International Airport, TX, February 17-18, 1996.
1996 Core faculty member, “Bipolar Disorder: Pharmacologic Treatment Options,” Pharmacy Educational Program available through the American Society of Health-System Pharmacists (developed program presented for peer review), Key Largo, FL, January 25-28, 1996.
1996-1998 Member / Pharmacy representative, Aggression Management Performance Improvement Team, John J. Madden Mental Health Center; Hines, IL.
1995-1998 Pharmacotherapy monitor as mandated by Nathan v. Levitt, John J. Madden Mental Health Center; Hines, IL
1995-1996 Co-chair, Pharmacy and Therapeutics / Drug Use Evaluation Committee, Chicago Metropolitan Child and Adolescent Services / The Psychiatric Institute; Chicago, IL
1994-1998 Paxil® Clinical Pharmacy Advisory Board member, SmithKline Beecham Pharmaceuticals; Philadelphia, PA
1994-1996 Co-chair, Great Lakes Psychopharmacy Update meetings, Continuing Education and Specialized Programming Committee, Conference of Psychiatric and Neurologic Pharmacists
1994-1998 Faculty advisor, Phi Chapter, Rho Chi Pharmacy Honor Society, College of Pharmacy, The University of Illinois at Chicago; Chicago, IL
1993-1995 Section editor, Psychiatric Disorders, In: Applied Therapeutics – The Clinical Use of Drugs, 6th edition (Kimble MA, Young LY, eds.), Applied Therapeutics, Inc.; Vancouver, WA
1993-1998 Faculty co-advisor, Delta Kappa Sigma Chapter, Rho Pi Phi Pharmaceutical Fraternity, College of Pharmacy, The University of Illinois at Chicago; Chicago, IL
1992-1998 Reviewer, Psychiatric Services (formerly Hospital and Community Psychiatry), American Psychiatric Association; Washington, DC
1991-1995 Member, Advisory Panel (Psychiatry) – Pharmacotherapy Self-Assessment Program, American College of Clinical Pharmacy; Kansas City, MO
1991 Clinical psychopharmacology consultant, Elisabeth Ludeman Developmental Center, Illinois Department of Mental Health and Developmental Disabilities; Park Forest, IL
Dr. Mark David Watanabe • Curriculum Vitæ • December, 2012 • page 5
1990-1998 Faculty committees, College of Pharmacy, The University of Illinois at Chicago; Chicago, IL •Student Faculty Relations Committee (1996-1998) •Scholarships and Awards Committee (1993-1995) •The Year of the Student Committee (1993-1994) •College Student Discipline Committee (1992-1993) •Department of Pharmacy Practice Faculty Advisory Committee (1992-1993) •Ad hoc committee on communication skills (1990)
1990-1998 Pharm.D. student advisor, College of Pharmacy, The University of Illinois at Chicago; Chicago, IL
1988-1990 Reviewer, Abstracts submitted for presentation at meetings of the American Society of Hospital Pharmacists. Annual Meetings: San Francisco, CA (1988), Nashville, TN (1989), Boston, MA (1990); Midyear Clinical Meetings: Las Vegas, NV (1990).
1988 Clinical psychopharmacology consultant, San Antonio State School; San Antonio, TX
1987-1989 Study coordinator for Phase I (chlorprothixene) pharmacokinetic, Phase II (tiospirone) efficacy, and Phase III (clozapine) efficacy studies at San Antonio State Hospital and Audie Murphy Veterans Administration Hospital; San Antonio, TX
1982-1983 Graduate student representative, Graduate Instruction and Research Committee Department of Pharmaceutical Chemistry University of California, San Francisco; San Francisco, CA
1978-1982 Pharmacy student leadership roles: •Student representative, Curriculum Review Committee •Senior Class President, Class of 1982 •Secretary / Treasurer, UCSF Chapter, Student Pharmaceutical Association University of California, San Francisco School of Pharmacy; San Francisco, CA
Community presentations
“What’s new in the world of psychiatric medications?” Presentation to a family support group of the Alameda County Mental Health Association, San Leandro, CA, June 13, 2002.
Client medication education group, Creative Living Center, Pleasanton, CA, May 21, 2002.
“An update on recent psychotropic medications.” Presentation to the National Alliance for the Mentally Ill – East Bay Chapter, Berkeley, CA, May 23, 2001.
“An overview of psychotropic medications.” Presentation to the clients of the Bay Area Community Services’ Towne House Residential Program, Oakland, CA, January 30, 2001.
Dr. Mark David Watanabe • Curriculum Vitæ • December, 2012 • page 6
“An overview of psychotropic medications.” Presentation to the African American Family Support Group, Alameda County Mental Health Association, Oakland, CA, September 26, 2000.
Client medication education group, Creative Living Center, Berkeley, CA, September 8, 2000.
“An overview of psychotropic medications: Older, current, and new medications pending FDA approval.” Presentation to the National Alliance for the Mental Ill – East Bay Chapter, Berkeley, CA, January 26, 2000.
“Depression and antidepressants.” Presentation to the East Bay Women’s Forum, Oakland, CA, September 28, 1999.
“Review of psychotropic medications,” lecture and discussion presented to the State of Illinois Guardianship and Advocacy Commission, John J. Madden Mental Health Center; Hines, IL, July 31, 1997.
Question and answer session on medications, Panic and Anxiety Disorder Support Group, Columbia-Woodland Hospital; Hoffman Estates, IL, November 7, 1996.
“Antidepressant medications: General considerations regarding the use of ‘first line’ agents in the treatment of major depression,” to the Erie Family Health Center; Chicago, IL, October 15, 1992.
“Medications and mental illness,” to the Hyde Park / Kenwood community at the First Unitarian Church of Chicago; Chicago, IL, March 25, 1990.
“The uses and abuses of over-the-counter drugs,” to the Parent / Teen Forum at the First Unitarian Church of San Antonio; San Antonio, TX, March 12, 1989.
SCHOLARLY ACTIVITIES:
PUBLICATIONS
Monographs / Continuing education articles
Watanabe MD. Bipolar disorder. Pharmacotherapy Self-Assessment Program, 6th edition (PSAP- VI), American College of Clinical Pharmacy, Lenexa, KS, 2007.
Watanabe MD. Bifeprunox: A partial dopamine-receptor agonist for the treatment of schizophrenia. Formulary 2007; 42: 371-377.
Watanabe MD. Antipsychotics: The treatment of schizophrenia. The Rx Consultant 2001; 11(5): 1-8.
Watanabe MD. Common anxiety disorders. The Rx Consultant 2000; 10(1): 1-8.
Watanabe MD. Schizophrenia and antipsychotic pharmacotherapy. The University of Illinois at Chicago College of Pharmacy FAX-CE Program, Winter 1998.
Watanabe MD. Atypical antipsychotics: Advancing the treatment of psychosis. KEEPOSTED (Official publication of the Illinois Council of Health-System Pharmacists), September 1997: 7-14.
Hartman T, Watanabe MD. Pharmacotherapy of depression: Focused considerations for primary care. J Am Pharm Assoc 1996; NS36(8): 521-533.
Dr. Mark David Watanabe • Curriculum Vitæ • December, 2012 • page 7
Malan RD, Watanabe MD. Advances in therapy of schizophrenia. U S Pharmacist 1996(3): HS13- HS28.
Watanabe MD. Schizophrenia. Pharmacotherapy Self-Assessment Program, 2nd edition (PSAP-II), American College of Clinical Pharmacy, Kansas City, MO, 1995.
Watanabe MD. The role of serotonin in depression and the use of selective serotonin reuptake inhibitors. The University of Illinois at Chicago College of Pharmacy Formulary Information Exchange / Continuing Education Program, 1992.
Watanabe MD. Antipsychotic medications: Their use in the treatment of schizophrenia. Amer Druggist 1992; 206(1): 86-100.
Watanabe MD. Schizophrenia. Pharmacotherapy Self-Assessment Program (PSAP), American College of Clinical Pharmacy, Kansas City, MO, 1992.
Ereshefsky L, Watanabe MD. Understanding schizophrenia. Sandoz Continuing Education series. Sandoz Pharmaceuticals Corporation, East Hanover, NJ, 1989.
Therapeutic position statements
Semla TP, Watanabe MD. ASHP Therapeutic Position Statement on the Recognition and Treatment of Depression in Older Adults. Am J Health-Sys Pharm 1998; 55: 2514-2518.
Literature reviews
Lenz K, Coderre K, Watanabe MD. Overview of depression and its management in children and adolescents. Formulary 2009; 44:172-180.
Watanabe MD. Pharmacotherapy for bipolar disorder: an updated review. US Pharm 2007; 32(11): 26-32.
Davis JM, Metalon L, Watanabe MD, Blake L. Depot antipsychotic drugs: Place in therapy. Drugs 1994; 47(5): 741-773.
Holland D, Watanabe MD, Sharma R. Atypical antipsychotics. Psychiatr Med 1991; 9(1): 5-24.
Ereshefsky L, Tran-Johnson TK, Watanabe MD. Current concepts in the treatment of schizophrenia: The pathophysiologic basis for atypical antipsychotic efficacy. Clin Pharm 1990; 9: 682-707.
Watanabe M, Davis JM. Overview: Pharmacotherapeutic considerations in the elderly psychiatric patient. Psychiatr Ann 1990; 20(8): 423-431.
Ereshefsky L, Watanabe MD, Tran-Johnson TK. Clozapine: An atypical antipsychotic. Clin Pharm 1989; 8: 691-709.
Dr. Mark David Watanabe • Curriculum Vitæ • December, 2012 • page 8
Book chapters
Watanabe MD. Drug Metabolism: Clinical scenario/outcome. In: Foye’s Principles of Medicinal Chemistry (7th edition; Lemke T, Williams DA, editors). Baltimore (MD): Lippincott Williams & Wilkins; 2013. Pp. 107, 188.
Watanabe MD. Hallucinogens, Stimulants, and Related Drugs of Abuse and Their Therapeutic Potential: Clinical scenario/outcome. In: Foye’s Principles of Medicinal Chemistry (7th edition; Lemke T, Williams DA, editors). Baltimore (MD): Lippincott Williams & Wilkins; 2013. Pp. 633, 656.
Watanabe MD, Winter ME. Tricyclic Antidepressants: Amitriptyline, Desipramine, Imipramine, and Nortriptyline. In: Basic Clinical Pharmacokinetics, 4th edition (Winter ME, ed.), Lippincott Williams & Wilkins; Baltimore, MD, 2004: 423-437.
Janicak PG, Watanabe MD. Farmacocinética, farmacodinamica e interações medicamentosas com o lítio. In: Interações Farmacológicas com Drogas Psiquiátricas (Marcolin MA, ed.), MEDSI Editora Médica e Científica Ltda.; Rio de Janeiro, Brazil, 1998: 109-127.
Furmaga KM, Watanabe MD. Secondary neuropsychiatric disorders. In: Applied Therapeutics – The Clinical Use of Drugs, 6th edition (Kimble MA, Young LY eds.), Applied Therapeutics, Inc.; Vancouver, WA, 1995: 79-1-79-7.
Janicak PG, Watanabe MD. Neuroleptic malignant syndrome. In: Psychiatry – Diagnosis and Therapy, 2nd edition (Flaherty JA, Davis JM, Janicak PG eds.), Appleton & Lange; Norwalk, CT, 1993: 459-463.
Watanabe MD. Headache. In: Clinical Pharmacy and Therapeutics, 5th edition (Gourley DR, Herfindal ET, Hart LL eds.), Williams and Wilkins; Baltimore, MD, 1992: 831-844.
Ortiz de Montellano PR, Stearns RA, Ator MA, Choe YS, Watanabe MD. “Hemoprotein Catalysis and Free Radical Formation.” In: Molecular Basis of the Action of Drugs and Toxic Substances. Proceedings, International Symposium – San Francisco, CA, April 23-26, 1987 (Singer TP, Castagnoli N, Wang CC eds.), Walter de Guyter; New York, NY, 1988.
Letters/Clinical commentaries
Watanabe MD. Clinical significance. 10. Drug Metabolism [Williams DA, au.] In: Foye’s Principles of Medicinal Chemistry, 6th edition (Lemke TL, Williams DA, Roche VF, Zito SW, eds.), Lippincott Williams & Wilkins; Philadelphia, PA, 2008: 254.
Original research activities
Sharma RP, Shapiro LE, Kamath SK, Soll EA, Watanabe MD, Davis JM. Acute dietary tryptophan depletion: Effects on schizophrenic positive and negative symptoms. Neuropsychobiol 1997; 35: 5- 10.
Ereshefsky L, Saklad SR, Watanabe MD, Davis CM, Jann MW. Thiothixene pharmacokinetic interactions: A study of enzyme inducers, clearance inhibitors, and demographic variables. J Clin Psychopharmacol 1991; 11: 296-301.
Dr. Mark David Watanabe • Curriculum Vitæ • December, 2012 • page 9
Ortiz de Montellano PR, Watanabe MD. Free radical pathways in the in vitro hepatic metabolism of phenelzine. Mol Pharmacol 1987; 31: 213-219.
Shetlar MD, Hom K, Carbone J, Moy M, Steady E, Watanabe M. Photochemical additions of amino acids and peptides to homopolyribonucleides of the major DNA bases. Photochem Photobiol 1984; 39: 135-140.
Original research abstracts
Sharma R, Shapiro L, Kamath S, Soll E, Watanabe M, Davis J. Acute dietary tryptophan depletion fails to benefit schizophrenia. Neuropharmacol 1994; 10 (3, suppl part 2): 205S.
Soll E, Kamath S, Sharma R, Shapiro L, Watanabe M, Davis J. Dietary depletion of tryptophan and plasma amino acid changes in schizophrenia. FASEB J 1994; 8(4): A429.
Ereshefsky L, Watanabe MD, Tran-Johnson TK, Jann MW, Saklad SR, Richards AL. Determinants of doxepin oral clearance: The effects of demographic variables and drug interactions. Pharmacotherapy 1988; 8(2): 134.
Case reports
Watanabe MD, Martin EM, deLeon OA, Gaviria M, Pavel DG, Trepashko DW. Successful methylphenidate treatment of apathy after subcortical CVA: Correlation with selective impairment of frontal-subcortical function. J Neuropsychiatry Clin Neurosci 1995; 7: 502-504.
PRESENTATIONS
Invited presentations
“The used to be just antidepressants: What’s different, what’s new?” Continuing education seminar for pharmacists sponsored by Eaton Apothecary, Burlington, MA. October 20, 2009.
“The CATIE trial: What did we learn about the effectiveness of antipsychotics?” Continuing education seminar for pharmacists sponsored by the School of Pharmacy, Office of Professional Learning Programs, Northeastern University and conducted at Clinical Pharmacy Services, University of Massachusetts Medical School, Shrewsbury, MA. October 14, 2009.
“The STAR*D trial: Effectiveness of sequential treatments for major depressive disorder.” Continuing education seminar for pharmacists sponsored by the School of Pharmacy, Office of Professional Learning Programs, Northeastern University and conducted at Clinical Pharmacy Services, University of Massachusetts Medical School, Shrewsbury, MA. May 13, 2009.
“Can I take my St. John’s wort with that? A review of psychotropic drug interactions.” Continuing education seminar for pharmacists sponsored by the School of Pharmacy, Office of Continuing Education, Northeastern University, Boston, MA. December 15, 2007.
“Cytochrome P450 101.” Continuing education seminar for pharmacists sponsored by the School of Professional and Continuing Studies, Northeastern University, Boston, MA. December 16, 2006.
“New perspectives of divalproex therapy in bipolar disorder.” Continuing education seminar for pharmacists sponsored by the School of Professional and Continuing Studies, Northeastern
Dr. Mark David Watanabe • Curriculum Vitæ • December, 2012 • page 10
University, Boston, MA. Locations: Veterans Affairs Medical Centers at Jamaica Plain, MA (November 7, 2006), Brockton, MA (November 8, 2006), and West Roxbury, MA (November 14, 2006).
“Gloom for the holidays: An overview of seasonal affective disorder.” Continuing education seminar for pharmacists sponsored by the Bouvé Institute for Healthcare Leadership and Professional Development, Northeastern University, Boston, MA, December 17, 2005.
“Managing the roller coaster of bipolar disorder.” Continuing education seminar for pharmacists sponsored by the Bouvé Institute for Healthcare Leadership and Professional Development, Northeastern University, Boston, MA, October 24, 2004.
“The treatment of aggression in individuals with developmental disabilities.” Continuing education seminar presented at the 8th Annual Northeastern Psychiatric Pharmacotherapy Symposium, Sturbridge, MA, September 17, 2004.
“Mood disorders and pulmonary disease.” Continuing education seminar for pharmacists sponsored by the Division of Adult and Continuing Education, Northeastern University, Needham, MA, March 30, 2004.
“Living on edge: Pharmacotherapy for an anxious age.” Continuing education seminar included in the program, “FOCUS 2000: Pharmacy in the New Millennium,” annual meeting of the California Society of Health-System Pharmacists, Oakland, CA, March 10, 2000.
“Ethnicity and Pharmacotherapy.” Co-presented workshop at the Cultural Competence and Mental Health Summit VII, Oakland, CA, November 30, 1999.
“A whirlwind tour of clinical psychopharmacology. II. The role of serotonin in the treatment of depression and anxiety.” Seminar presented for psychiatry residents of the University of California, Davis Medical Center and attending psychiatrists at the Sacramento County Mental Health Treatment Center, Sacramento, CA, January 7, 1999.
“A whirlwind tour of clinical psychopharmacology. I. The cytochrome P450 system and associated drug-drug interactions.” Seminar presented for psychiatry residents of the University of California, Davis Medical Center and attending psychiatrists at the Sacramento County Mental Health Treatment Center, Sacramento, CA, October 22, 1998.
“Atypical antipsychotics: The serotonin-dopamine antagonists.” Seminar presented for Grand Rounds at Chicago-Read Mental Health Center, Chicago, IL, March 25, 1998.
“Drug interactions: The cytochrome P450 system.” Seminar presented at the 1997 Great Lakes Psychopharmacy Conference, Chicago, IL, September 12, 1997.
“Schizophrenia and other psychotic disorders.” Lecture included in the Psychiatric Pharmacy Board Certification Examination Review Course sponsored by the American Society of Health- System Pharmacists, Minneapolis, MN, June 1, 1997.
“Traditional therapies for schizophrenia.” Continuing education seminar included in the program, “Recent Breakthroughs in the Treatment of Schizophrenia,” sponsored by the University of Illinois at Chicago College of Pharmacy, Northbrook, IL, April 24, 1997.
Dr. Mark David Watanabe • Curriculum Vitæ • December, 2012 • page 11
“Bipolar disorder: Pharmacologic treatment options.” Continuing education seminar sponsored by the American Society of Health-System Pharmacists for the Polish American Pharmacists Association, Chicago, IL, March 19, 1997.
“Bipolar disorder: Pharmacologic treatment options.” Continuing education seminar sponsored by the American Society of Health-System Pharmacists for the Northeastern Illinois Pharmacists Association, Lake Zurich, IL, February 19, 1997.
“The Brief Psychiatric Rating Scale for beginners.” Workshop presented at the 1997 National Symposium for Psychiatric Pharmacy Practitioners, Athens, GA, February 4, 1997.
“The pharmacotherapy of schizophrenia: Tentative traditions and future frontiers.” Continuing education seminar sponsored by the Delta Kappa Sigma Alumni Chapter of Rho Pi Phi Pharmaceutical Fraternity, Advocate-Lutheran General Hospital, Park Ridge, IL, November 21, 1996.
“Bipolar disorder: Pharmacologic treatment options.” Continuing education seminar sponsored by the American Society of Health-System Pharmacists for the Northern Illinois Society of Health-System Pharmacists, Advocate-Lutheran General Hospital, Park Ridge, IL, November 19, 1996.
“Bipolar disorder: Pharmacologic treatment options.” Continuing education seminar sponsored by the American Society of Health-System Pharmacists for pharmacists in the Kankakee County (Illinois) area, Bradley, IL, October 30, 1996.
“Use of psychometric rating scales for longitudinal assessment of depression.” Workshop presented at the 1996 National Symposium for Mental Health / Developmental Disabilities / Substance Abuse Pharmacists, Athens, GA, February 7, 1996.
“Psychopharmacology update.” Seminar presented at the 1995 Recent Clinical Updates in Developmental Disabilities Symposium, Southern Illinois University School of Medicine, at the University of Illinois at Springfield, Springfield, IL, October 12, 1995.
“Schizophrenia: Treatment options for the ‘90’s.” Continuing education seminar sponsored by the University of Illinois at Chicago College of Pharmacy for the Chicagoland Veterans Affairs Medical Centers, Northbrook, IL, October 11, 1995.
“Outcome studies in mentally ill populations.” Workshop presented at the 1995 Great Lakes Psychopharmacy Update, Toledo, OH, June 9, 1995.
“New medications in development for mental illness.” Seminar presented at the 1995 National Symposium for Mental Health / Developmental Disabilities / Substance Abuse Pharmacists, Athens, GA, January 31, 1995.
“Antipsychotic dosing guidelines.” Workshop presented at the Sixth Psychopharmacy Update, Austin, TX, September 30, 1994.
“The pharmacotherapy of apathy in frontal lobe syndromes.” Seminar presented at the Second Annual Conference on Clinical Practice in Neuropsychiatry: Frontiers in Neuropsychiatry, Chicago, IL, December 10, 1993.
Dr. Mark David Watanabe • Curriculum Vitæ • December, 2012 • page 12
“Case presentation: Pharmacological management of a neuropsychiatric patient.” Case presentation given at the 2nd Annual Conference of the American Society of Hispanic Psychiatry, Chicago, IL, October 14, 1993.
“Costs of depression vs. patient outcomes.” Seminar presented at the Midwest Managed Health Care Congress, Chicago, IL, September 8, 1993.
“Novel antidepressants: Sertraline and S-adenosylmethionine.” Seminar presented to the Medical Staff at Tinley Park Mental Health Center, Tinley Park, IL, June 20, 1991.
“Beyond Valium®: Old and new approaches to the pharmacotherapy of generalized anxiety disorder.” Seminar presented at the Mini-Conference for Pharmacists of the Illinois Department of Mental Health and Developmental Disabilities, Springfield, IL, April 3, 1990.
“The clinical challenges of schizophrenia: An overview for the practicing pharmacist.” Continuing education seminar presented at the American Pharmaceutical Association Annual Meeting, Washington, DC, March 10, 1990.
Videotaped continuing education program
“Advances in Determining and Treating Schizophrenia: Pathophysiology.” A videotaped continuing education presentation produced and distributed by MEDIVISION, Houston, TX, April 15, 1997.
“Advances in Determining and Treating Schizophrenia: Novel Antipsychotics.” A videotaped continuing education presentation produced and distributed by MEDIVISION, Houston, TX, April 15, 1997.
Poster presentations
DiVall MV, Stevens C, Zilberman E, Edwards R, Kirwin J, Watanabe MD. Teaching student pharmacists to develop an evidence-based public health program to impact a vulnerable population. Am J Pharm Educ 2011; 75(5): Article 105, p. 115.
Kirwin JL, DiVall MV, Douglass M, Gonyeau M, Jacobs M, McQueeney M, Skirvin JA, Van Amburgh JA, Watanabe MD, Zgarrick DP. Curricular revision incorporating pathophysiology, pharmaceutical care skills, self-care, and pharmacotherapeutics to enhance content delivery. Am J Pharm Educ 2011; 75(5): Article 105, p. 131.
Watanabe MD, Ereshefsky L, Saklad SR et al.: “Comparative efficacy of the atypical antipsychotic, tiospirone.” Poster presentation to ALCALDE III, Southwest Leadership Conference for Pharmacy Residents, Fellows, and Preceptors, Dallas, TX, March 30, 1989.
Watanabe MD, Ortiz de Montellano PR: “The effect of deuterium substitution on phenelzine metabolism.” Poster presentation to the Annual Meeting of the Society of Toxicology, San Diego, CA, March 25, 1985.
P latform presentations
Del Paggio D, Watanabe M. “Psychotropic medication monitoring: Design, implementation, and outcome in a county mental health system.” Presented at the 38th Annual Midyear Clinical
Dr. Mark David Watanabe • Curriculum Vitæ • December, 2012 • page 13
Meeting of the American Society of Health-System Pharmacists, New Orleans, LA, December 9, 2003.
Watanabe MD, Ereshefsky L et al.: “Determinants of doxepin clearance: The effects of demographic variables and drug interactions.” Platform presentation to the 9th Annual Meeting of the American College of Clinical Pharmacy, Philadelphia, PA, July 27, 1988.
Ortiz de Montellano PR, Grab LA, Komives EA, Stearns RA, Watanabe MD: “A bestiary of cytochrome P-450-destructive species.” Contribution to platform presentation to the 41st Northwest Regional Meeting of the American Chemical Society, Portland, OR, June 16, 1986.
PROFESSIONAL AFFILIATIONS:
•American Association of Colleges of Pharmacy; member, Council of Faculties •American College of Clinical Pharmacy; member, Central Nervous System Practice and Research Network •American Pharmacists Association; member, Section on Clinical Sciences •American Society of Health-System Pharmacists; member, Section of Clinical Specialists •College of Psychiatric and Neurologic Pharmacists; Founding Member •Massachusetts Pharmacists Association •National Pharmaceutical Association •Rho Chi Pharmacy Honor Society •Phi Lambda Sigma Pharmacy Leadership Society •University of California, San Francisco Pharmacy & Graduate Alumni Associations •National Alliance for the Mentally Ill – Massachusetts (healthcare professional member)
HONORS AND AWARDS:
•Golden Apple Teaching Award; The University of Illinois at Chicago College of Pharmacy (1994) •Long Foundation Award for Excellence in Teaching; University of California, San Francisco (1983) •Regents Scholar; University of California, San Francisco (1979-1982) •Dean’s Honor List; University of California, Irvine (1973-1977) •Listed in Who’s Who in Medicine and Healthcare, 8th edition (2011-2012) •Listed in Who’s Who in American Education, 7th edition (2006-2007) •Listed in Who’s Who in America, 65th edition (2011) •Listed in Who’s Who in the World, 30th edition (2013)
121220/mdw
Dr. Mark David Watanabe • Curriculum Vitæ • December, 2012 • page 14